Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05457465 · ClinicalTrials.gov registry record · Phase 2
Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder
A Phase 2 study of Bipolar Disorder, sponsored by Mclean Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05457465 is a Phase 2 study of Bipolar Disorder that is actively recruiting participants, run by Mclean Hospital. The registered enrollment target is 25 participants, below the 333-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05457465, a Phase 2 study of Bipolar Disorder, is actively recruiting participants, sponsored by Mclean Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Preliminary data have suggested that cannabidiol (CBD) may have a number of clinical benefits, including anti-anxiety and antidepressant properties. This study is a pilot open-label clinical trial assessing a custom-formulated high-CBD product over the course of 4 weeks in patients with bipolar disorder who experience anxiety.
Conditions Studied
Interventions
- DRUG Cannabidiol
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-06-01 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05457465
The ClinicalTrials.gov registry entry for NCT05457465 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 333-participant average among 162 other Bipolar Disorder trials with a reported enrollment target (92% lower). The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bipolar Disorder appearing as the primary indexed condition, and to 1 intervention - of which Cannabidiol is the first listed.
NCT05457465 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05457465 about?
NCT05457465 is a clinical study titled "Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder". Preliminary data have suggested that cannabidiol (CBD) may have a number of clinical benefits, including anti-anxiety and antidepressant properties. This study is a pilot open-label clinical trial assessing a custom-formulated high-CBD product over the course of 4 weeks in patients with bipolar diso...
What is the current status of trial NCT05457465?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2023-06-01. Estimated completion is 2025-12.
What conditions does trial NCT05457465 study?
This clinical trial studies the following conditions: Bipolar Disorder.
What interventions are being tested in trial NCT05457465?
The interventions under investigation include: Cannabidiol (DRUG).
Who is sponsoring clinical trial NCT05457465?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05457465 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bipolar Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Correcting Circadian Rhythms to Breakthrough in Bipolar Disorder
RECRUITING · Phase 2
-
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
RECRUITING · Phase 2
-
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
RECRUITING · Phase 2
-
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
RECRUITING · Phase 2
-
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
RECRUITING · Phase 2
-
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.